33 results on '"Petito V"'
Search Results
2. T.08.9: SPECIFIC GUT MICROBIOTA SIGNATURES ARE ASSOCIATED WITH SYMPTOMATIC LACTOSE MALABSORPTION
3. T.06.3 EMERGING ROLE OF IL-33/ST2 AND GUT MICROBIOTA AXIS IN THE INFLAMMATORY PROCESS OF ULCERATIVE COLITIS PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS
4. OC.04.3 REAL-LIFE VS TRIAL ACCESS TO BIOLOGIC THERAPY DIFFERENCES: A 2019-2020 EXPERIENCE IN AN ITALIAN TERTIARY IBD CENTER
5. OC.08.6 IMMUNE AND NON IMMUNE CHANGES FOLLOWING FMT IN EXPERIMENTAL COLITIS: EMERGING PATHWAYS OF FMTDERIVED MUCOSAL HEALING
6. OC.10.6 THE ROLE OF OCTN1 IN PREDICTING INDIVIDUAL RESPONSE TO THERAPY IN ULCERATIVE COLITIS: TOWARDS A PERSONALIZED APPROACH
7. OC.02.5 THE SOLUTE CARRIER LC22A4/OCTN1 AS A NOVEL IBD DETERMINANT AT THE MICROBE-HOST INTERFACE
8. OC.05.5 ALTERATION IN THE ABUNDANCE OF AKKERMANSIA MUCINIPHILA IS ASSOCIATED TO GASTROINTESTINAL AND EXTRA-INTESTINAL DISEASES: TOWARDS THE IDENTIFICATION OF SPECIFIC MICROBIAL SIGNATURES OF DISEASE
9. OC.04.1 MOLECULAR PATHWAYS OF SARCOPENIA IN DSS ACUTE MODEL OF MURINE COLITIS
10. OC.04.5 IL-33/ST2 LEVELS AND GUT MICROBIOTA CHARACTERIZATION CAN PREDICT MUCOSAL RESPONSE TO ANTI-TNF THERAPY IN ULCERATIVE COLITIS
11. P.07.20 FATIGUE AS A POSSIBLE MARKER OF SARCOPENIA IN INFLAMMATORY BOWEL DISEASE PATIENTS
12. OC.16.1 ALTERATIONS IN CYTOKINE EXPRESSION PROFILE IN COLON MUCOSA OF IBD PATIENTS AND IN RESPONSE TO ANTI-TNF-A TREATMENT
13. P.07.10 OCULAR MANIFESTATIONS IN A TERTIARY IBD CENTER: BETTER TO KEEP AN EYE ON
14. OC.10.2 ANTI-TNF-ALPHA THERAPY INDUCES MICROBIAL AND IMMUNOLOGICAL CHANGES IN DEXTRAN SODIUM SULPHATE CHRONIC COLITIS
15. OC.16.6 EMERGING ROLE OF IL-33/ST2 LEVELS IN PREDICTING MUCOSAL RESPONSE TO ANTI-TNF THERAPY IN ULCERATIVE COLITIS
16. OC.12.1 THE IMPACT OF TROPHIC EFFECTS OF MULTI STRAIN PROBIOTIC PREPARATION ON PARACELLULAR PERMEABILITY
17. OC.14.6: Escherichia Coli Nissle 1917 Modulate GUT Microbiota Composition in Ulcerative Colitis Patients
18. P.05.8: Clausii in Colitis: Role and Mechanisms of Action of Bacillus Clausii in Experimental Colitis
19. P.05.9: Colitis is Associated with Muscle Function Alteration: Emerging Mechanisms of Asthenia in IBD?
20. P.03.12: Breath Methane Production in Lactulose Breath Test is Affected by Gender, a Post HOC Italian Study
21. The gut microbiota of cirrhotic patients with poor nutritional status: Preliminary evidences
22. P.01.9 THE GUT MICROBIOTA OF CIRRHOTIC PATIENTS WITH POOR NUTRITIONAL STATUS: PRELIMINARY EVIDENCES
23. P.09.15 INCREASED ABUNDANCE OF BENEFICIAL BACTERIA IS ASSOCIATED WITH CLINICAL IMPROVEMENT AFTER RIFAXIMIN TREATMENT
24. P.07.1 GUT MICROBIOTA MOLECULAR SPECTRUM IN HEALTHY CONTROLS, DIVERTICULAR DISEASE, IBS AND IBD PATIENTS: TIME FOR MICROBIAL MARKER OF GASTROINTESTINAL DISORDERS?
25. First steps towards understanding the dynamic evolution of gut microbiota in different stages of liver disease
26. OC.16.4 DIRECT ROLE OF INFLIXIMAB ON INTESTINAL MUCOSA SUSTAINS MUCOSAL HEALING: EXPLORING NEW MECHANISMS OF ACTION
27. P.06.9 INFLIXIMAB IS NOT INCREASING COLONIC CANCER RISK ASSOCIATED TO CHRONIC COLITIS IN MICE
28. P.03.1 INFLIXIMAB (IFX) ACTS LOCALLY ON INTESTINAL MUCOSA AND ITS PHARMACOKINETIC IS DIFFERENT IN DSS COLITIC MICE COMPARED TO CONTROLS
29. OC.07.6 GELENTERUM AMELIORATES SEVERITY OF COLITIS IN DSS MURINE MODEL, WHILE MODULATING GUT MICROBIOTA AND INTESTINAL MUCUS LAYER
30. P.16.1 INFLIXIMAB AND TNF ALFA MEASUREMENT IN INTESTINAL MUCOSA OF IBD PATIENTS: A NEW TOOL FOR THE CLINIC?
31. P.06.5 DIRECT EFFECTS OF INFLIXIMAB (IFX) ON INTESTINAL MUCOSA: EXPLORING MECHANISMS OF MUCOSAL HEALING
32. P.1.188: EFFECTS OF INFLIXIMAB (IFX) ON INTESTINAL EPITHELIAL CELLS: EXPLORING MECHANISMS OF MUCOSAL HEALING
33. P.1.202: TANAGEL REDUCES COLITIS SEVERITY IN DEXTRAN SODIUM SULPHATE (DSS) MODEL OF MURINE ACUTE COLITIS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.